Financial Update from Cadrenal Therapeutics
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD), a leader in biopharmaceuticals, shared its financial results for the third quarter of 2025. The company is notable for developing groundbreaking therapeutics aimed at addressing significant gaps in anticoagulation therapy. This report outlines their progress and future strategies for their leading products: tecarfarin and frunexian.
Recent Advancements in Clinical Development
This quarter marks a crucial progression in the clinical development of tecarfarin. Notably, the manufacturing of the drug product has been successfully completed under stringent current good manufacturing practices (cGMP).
Ongoing Clinical Trials
Cadrenal is actively engaged in a single-site Phase 2 study of tecarfarin, focusing on patients with left ventricular assist devices (LVADs). This collaboration with Abbott exemplifies their commitment to addressing unmet medical needs.
Future Studies for Dialysis Patients
Furthermore, the company is in discussions with investigators regarding a potential multi-site Phase 2 study of tecarfarin for dialysis patients who have been previously treated with warfarin. These efforts signify Cadrenal's dedication to targeting various patient demographics.
Expanding the Product Portfolio
In September, Cadrenal Therapeutics expanded its portfolio by acquiring the assets of eXIthera Pharmaceuticals. This acquisition includes a unique pipeline of investigational intravenous (IV) and oral Factor XIa inhibitors.
Introducing Frunexian
The lead asset from this acquisition, frunexian, stands out as a first-in-class, Phase 2-ready IV Factor XIa inhibitor tailored for acute care settings. It aims to conquer situations where medical devices significantly influence coagulation, such as during cardiopulmonary bypass or catheter thrombosis.
CEO Quang X. Pham’s Vision
Quang X. Pham, the Chairman and CEO, articulated the company's strategic positioning to meet gaps in anticoagulation treatment for various indications. He emphasized the development of two differentiated anticoagulants (tecarfarin and frunexian) and the importance of regulatory pathways in achieving their clinical milestones.
Financial Highlights for Q3 2025
For the quarter ending September 30, 2025, Cadrenal reported:
- Research and development expenses of $0.7 million, a slight decrease from $0.8 million in 2024.
- General and administrative expenses amounted to $2.0 million, rising from $1.7 million in the previous year.
- A net loss recorded at $2.7 million, compared to $2.4 million for the same quarter in the prior year.
Cash Position and Outstanding Shares
As of September 30, 2025, Cadrenal reported cash and cash equivalents totaling $3.9 million, with approximately 2.1 million shares of common stock outstanding.
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics is committed to innovating unique biopharmaceutical products that address critical gaps in acute and chronic anticoagulant therapy. Their focus on developing novel anticoagulants intends to improve safety and efficacy for patients in need. The two primary assets in their portfolio are tecarfarin and frunexian, targeting both chronic and acute use populations.
Frequently Asked Questions
What is the main focus of Cadrenal Therapeutics?
Cadrenal focuses on developing advanced therapeutics that address gaps in anticoagulation therapy.
What recent acquisition did Cadrenal Therapeutics make?
Cadrenal acquired eXIthera Pharmaceuticals, enhancing its portfolio with new anticoagulant therapies.
When did Cadrenal report its financial results for Q3 2025?
Cadrenal announced its third-quarter results on November 10, 2025.
What is tecarfarin?
Tecarfarin is an oral vitamin K antagonist developed for chronic use in anticoagulation therapy.
How much cash does Cadrenal have as of September 30, 2025?
Cadrenal reported cash and cash equivalents totaling $3.9 million as of September 30, 2025.
